Swedencare´s subsidiary Vetio receives Intention to Grant from the European Patent Office (EPO) and Notice of Allowance from the United States Patent Office (USPTO) for its Starch-Free Soft Chew
Montreal, Quebec (June 28, 2022) Swedencare´s subsidiary Vetio has received an Intention to Grant from the European Patent Office (EPO) and a Notice of Allowance from the United States Patent Office (USPTO) for its Starch-Free Soft Chew for Veterinary Applications. Vetio’s Soft Chew Technology platform for Animal Health is ideally suited for delivering one or more active ingredients in a veterinary pharmaceutical-grade dosage form.
According to scientist Gueorgui Puchkarov, “Vetio’s novel composition and process contains no starch and no added water, making it well suited for moisture sensitive active ingredients”. Puchkarov added that “the composition of ingredients produces a texture that remains soft and malleable over time, allowing for excellent stability, bioavailability, and allows for in-vitro dissolution methods of discriminating nature as a means of quality control.”
Alain Dugal, General Manager of Vetio Animal Health’s Montreal pharma operations, commented “Vetio offers end-to-end CDMO services for Animal Health and has all of the tools in-house to develop and commercially manufacture the very best companion animal soft chew drug products”.
Dugal added that “Vetio’s soft chew is a premium delivery system, capable of delivering multiple APIs in a highly palatable matrix based on Vetio’s own FlavorPal line of palatants.
About Vetio
Vetio is a Contract Development and Manufacturing Organization (CDMO) that specializes in complex drug product formulation and manufacturing of veterinary pharmaceutical, supplement, and dermatology products. Vetio is committed to the development and manufacturing of products that improve the lives of animals, while assuring the safety, quality, and compliance of our products to the highest industry standards. Vetio is a wholly-owned subsidiary of Swedencare.